文献速递甲状腺疾病

分子数据在甲状腺结节与甲状腺癌中的临床应用

Clinical use of Molecular Data in Thyroid Nodules and Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

针对细胞学不确定的甲状腺结节,目前有3种商业分子检测(ThyroSeq v.3、Afirma基因测序分类器、ThyGeNEXT/ThyraMIR),主要用于排除Bethesda III和IV结节的恶性,因均具有高敏感性和高阴性预测值。在晚期甲状腺癌使用特异性单激酶抑制剂(如selpercatinib用于RET改变甲状腺癌)前,分子检测至关重要。

要点

  • 3种商业分子检测用于细胞学不确定甲状腺结节,以排除Bethesda III和IV结节的恶性。
  • 这些检测在美国的普遍使用显著减少了良性结节的不必要甲状腺手术。
  • 使用特异性单激酶抑制剂前,晚期甲状腺癌患者必须进行分子检测以确认靶点。

核心结论

  • 分子检测主要用于排除Bethesda III和IV甲状腺结节的恶性,并指导晚期甲状腺癌的靶向治疗决策。

研究设计与样本

  • 本文为小型综述,讨论分子数据在甲状腺结节和甲状腺癌不同临床情境中的应用。

主要发现

  • 分化型甲状腺癌发病的主要驱动因素是MAPK和PI3K/Akt通路组分的单点突变和基因融合。
  • 更晚期甲状腺癌的其他重要遗传改变包括TERT启动子、TP53、EIF1AX及表观遗传改变。
  • 3种商业检测包括基于DNA/RNA的ThyroSeq v.3、基于RNA的Afirma基因测序分类器和DNA/miRNA混合检测ThyGeNEXT/ThyraMIR。
  • 这些检测均具有高敏感性和高阴性预测值,主要用于排除Bethesda III和IV甲状腺结节的恶性。
  • 在美国的普遍使用已显著减少良性结节的不必要甲状腺手术;部分检测还可提供甲状腺癌的分子驱动信息,可能支持初始管理决策,但该实践尚未广泛采用。

关键数值与推荐

  • 细胞学不确定甲状腺结节使用3种商业分子检测(ThyroSeq v.3、Afirma基因测序分类器、ThyGeNEXT/ThyraMIR)排除恶性。
  • 使用特异性单激酶抑制剂(如selpercatinib用于RET改变甲状腺癌)前,晚期甲状腺癌患者必须进行分子检测。

临床怎么用

  • 分子检测用于Bethesda III和IV甲状腺结节以排除恶性,减少不必要手术。
  • 晚期甲状腺癌患者在使用特异性单激酶抑制剂前应进行分子检测以确认靶点。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Over the past 3 decades, advances in the molecular genetics of thyroid cancer (TC) have been translated into diagnostic tests, prognostic markers, and therapeutic agents. The main drivers in differentiated TC pathogenesis are single-point mutations and gene fusions in components of the Mitogen-activated protein kinase (MAPK) and phosphoinositide-3-kinase-protein kinase B/Akt (PI3K/Akt) pathways. Other important genetic alterations in the more advanced types of TC include TERT promoter, TP53, EIF1AX, and epigenetic alterations. Using this knowledge, several molecular tests have been developed for cytologically indeterminate thyroid nodules. Currently, 3 commercially available tests are in use including a DNA/RNA-based test (ThyroSeq v.3), an RNA-based test (Afirma Gene Sequencing Classifier), and a hybrid DNA/miRNA test, ThyGeNEXT/ThyraMIR. These tests are mostly used to rule out malignancy in Bethesda III and IV thyroid nodules because they all have high sensitivities and negative predictive values. Their common use, predominantly in the United States, has resulted in a significant reduction in unnecessary thyroid surgeries for benign nodules. Some of these tests also provide information on the underlying molecular drivers of TC; this may support decision making in initial TC management planning, although this practice has not yet been widely adopted. More importantly, molecular testing is essential in patients with advanced disease before using specific mono-kinase inhibitors (eg, selpercatinib for RET-altered TC) because these drugs are ineffective in the absence of a specific molecular target. This mini-review discusses the utilization of molecular data in the clinical management of patients with thyroid nodules and TC in these different clinical situations.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Alzahrani AS. Clinical use of Molecular Data in Thyroid Nodules and Cancer. J Clin Endocrinol Metab. 2023. PMID: 37200449. doi:10.1210/clinem/dgad282

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。